“Given that approach by [Regen] there does not seem to me anything even approaching a good reason to extend the time for payment of the£225,000 , whether until the outcome of the appeal or for any other period.”
“Q. If RegenLab wanted to, would it be able to pay that 225,000 pounds? A. Of course. … Q. Is RegenLab seeking finance to enable itself to pay the 225,000 pound [sic] ordered by the U.K. court? A. No.”
“Despite the withdrawal of the current ITC (see above), Regen will continue enforcement of its patent rights in Europe and the USA. Regen is seeking damages for at least 10 million USD for patent infringement by Estar since 2008 and reimbursement of all legal costs incurred. It appears that the only activity of Estar is to commercialise copycats of Regen’s products. It would therefore be desirable for the PRP [platelet rich plasma] industry that Estar disappears from the market.”
“In view of the aforementioned, it was and is still impossible for Regen to meet the deadlines as set forth in the schedule. Regen will not be able to prepare bundles for tomorrow, March 4 2020 and to prepare appropriately for the April 1, 2020 deadline. Rights of Regen in order to appropriately prepare for the Appeal have been restricted in a substantial manner. As mentioned in Regen’s application, if the Appeal is not stayed (as in France and German[y]) then Regen requests a delay, a new schedule for the Appeal and postponement of the Appeal.”